|Biotech Due Diligence||
It is still a work in progress, but please visit and provide feedback on the brand new Sarepta Therapeutics $SRPT stock research page. SRPT has of course been prominently in the news as they have released promising data for eteplirsen, their antisense drug for Duchenne muscular dystrophy (DMD). You'll find a collection of articles analyzing the data and the stock, basic information presented by the company recently, scientific and medical conference presentations, etc. In other words, all of the due diligence resources you've come to expect from BiotechDueDiligence.
Your comment will be posted after it is approved.
Leave a Reply.